Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This phase III study is designed as a double blind, randomized, multi-nation, multi-center,
placebo controlled clinical research, which aims to evaluate the safety and efficacy of
Dantonic® (T89) in patients with chronic stable angina pectoris.